Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD)

By sjmartinez • April 25, 2025

Aggarwal R, Pongtarakulpanit N, Sullivan DI, Moghadam-Kia S, Bae SS, Wilkerson J, Saygin D, Marder G, Venuturupalli S, Dellaripa PF, Danoff SK, Doyle T, Hunninghake GM, Lee JS, Fischer A, Falk J, Johnson C, Koontz D, Ascherman DP, Oddis CV. Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD). Rheumatology (Oxford). 2025 Apr 24:keaf218. doi: 10.1093/rheumatology/keaf218. Epub ahead of print. PMID: 40272902.

Tags: abatacept, anti-synthetase syndrome, Cedars Sinai DoM, Idiopathic inflammatory myopathy, interstitial lung disease, placebo-controlled trial, Publications, Pulmonary, Critical Care & Sleep Medicine, randomized, Rheumatology

Related Posts

Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous ECG Monitoring Follow-Up: ADVANTAGE AF-Phase 2

Reddy VY, Gerstenfeld EP, Schmidt B, Andrade JG, Nair D, Natale A, Saliba W, Sommer P, Metzner A, Verma A, Hounshell T, Amin A, Gentlesk[...]

Development and Validation of Crohn’s Perianal Fistula Educational Videos and Website for Increasing Patient Knowledge and Engagement

Khalil C, Mehra M, Yang Y, Choi SY, Ballesteros J, Krut Z, Bonthala N, Zaghiyan K, Gu P, Yeo YH, Spiegel BMR, Almario CV. Development[...]

Noninvasive Assessment of β-Secretase Activity Through Click Chemistry-Mediated Enrichment of Neuronal Extracellular Vesicles to Detect Alzheimer’s Disease

Kim H, Lee J, Qian A, Ji YR, Zhang R, Hu Q, Williams CK, Chuang HY, Smalley MD, Xu Y, Gao L, Mayo MC, Zhang[...]